Inphena

Connecting patients, doctors and treatments.

We are a danish specialty pharmaceutical company with a strong interest to bring patients and doctors the best treatment options
We work closely with doctors and patients to identify what treatments that are best for them

About

Inphena is short for International Pharmaceutical Enabling 
We were founded in 2017 by Soren Anker Nielsen and Dr. Claus Moller, and are currently owned by 5 individuals, where 4 work in or with the company
 
The aim with Inphena is to listen closely to doctors, researchers and patients to identify novel treatments, in particular within: 
Oncology and supportive care
CNS – Addiction and Pain
Womens Health

Health

People

Global

Security

safe android app aplication phone
Lineal_Expand

2017

Founded

Founded by Dr. Claus Moller and Soren Anker Nielsen, Richard Poulsen as CEO

2017
Lineal_Expand

2019

Norge AS

We founded Inphena Norge AS with base in the Oslo Science Park

2019
Lineal_Expand

2019

R&D

Initiated two R&D projects

2019
Lineal_Expand

2020

On the market

We have brought products on the market in Denmark and Norway

2020
Lineal_Expand

2021

CEO

Soren Anker Nielsen is appointed CEO and Chairman

2021
Lineal_Expand

2021

License

License agreement with Adalvo

2021
Lineal_Expand

2021

DAM program

Start of DAM program in Norway with the Norwegian government

2021
Lineal_Expand

2022

Expansion

Expansion into MENA and GCC

2022
Lineal_Expand

2022

Unicef

Long Term Agreement with UNICEF

2022

progressive mindset

Inphena is short for International Pharmaceutical Enabling 
We were founded in 2017 by Soren Anker Nielsen and Dr. Claus Moller, and are currently owned by 5 individuals, where 4 work in or with the company
 
The aim with Inphena is to listen closely to doctors, researchers and patients to identify novel treatments, in particular within: 
Oncology and supportive care
CNS – Addiction and Pain
Womens Health

News

INPHENA signs LTA with UNICEF

Inphena has signed a long term agreement with UNICEF for supply of products within opioid addiction through UNICEF. This follows an extensive due diligence process involving all of Inphenas business and suppliers. “We are very proud to reach this agreement. Having an addict within a family, is an immense stress to the whole family, and in particular for the children. Anything that can be done to remediate this, will provide a lift in the quality of life for the families” says CEO, Soren Anker Nielsen. 

DAM in Norway

Inphena has been working for some years with the Norwegian specialists within addiction treatment to set up a HAT program in Norway. The decision was taken by the government to implement a program, and Inphena was chosen to help and implement this program. 

Expansion

Inphena has expanded the product offering and competencies available by entering into a number of partnerships with individuals, organisations and associations. This enables us to execute competent training and offer a portfolio of products within the area of opioid addiction. In addition, our suply chain has been strengthened for our own developed products. 

Want to learn more?

We look forward to meet you, and introduce you to patient and doctor driven healthcare solutions.

Connecting patients, doctors and treatments for the best possible solution.


We are based at the DTU Science Park near Copenhagen, Denmark, and at the Research park in Oslo, Norway, and are working internationally for the best possible solutions.

health

People

Global

Security

safe android app aplication phone

Contact